Novartis (NVS) has released an update.
Novartis has reported a robust second quarter in 2024, with net sales increasing by 11% and core operating income margin nearing 40%. This surge is credited to strong performances from key products, prompting the company to raise its full-year 2024 earnings outlook. Additionally, Novartis has made significant progress in advancing its medical pipeline with multiple FDA submissions and approvals.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.
